As an infrastructure at the German Center for Infection Research (DZIF), the Clinical Trial Unit tracks DZIF's study activities in the “Healex Site Management System (SMS)”. Studies are sorted by indication and are continuously updated.

The study register has recently been expanded to include the category “COVID-19”. For the first time, not only DZIF study activities are presented here: In order to provide a comprehensive overview in the current pandemic situation of planned and already active COVID-19 studies in Germany, the Clinical Trial Unit is cooperating with researchers from various German Centers for Health Research and other networks.

For researchers: If your study is not yet included in our portal, please contact the project management of the Clinical Trial Unit (angela.steinbach@uk-koeln.de or vassiliki.dimitriou@uk-koeln.de).

COVID-19 Clinical Trials Master Protocol

AcronymISRCTNEudraCTNCT (clinicaltrials.gov)DRKS

A Multi-center, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients

Status: Active

Purpose / Objectives

Primary Outcome

Protocol according to the master protocol “A Multi-center, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients”

Based on the recently published WHO master protocol, the BIH Clinical Study Center (BIH CSC) has developed a central COVID-19 master protocol  to  harmonize and speed up initiation of COVID-19 clinical trials. The master protocol is available from CSC or via covid19-researchboard@charite.de .

Diagnosis

Depending individual clinical trial

Patient attributes

Inclusion criteria

Depending on individual clinical trial

Exclusion criteria

Depending on individual clinical trial

Documents (password protected)

Responsibilities in overall trial